Inventage Lab

Inventage Lab EBIT per Employee

The EBIT per Employee of Inventage Lab (389470.KQ) as of Oct 21, 2026 is -430.02 M KRW. In the previous year, EBIT per Employee was -269.21 M KRW — a change of 59.73% (lower).

EBIT per Employee

-430.02 MKRW

YoY

59.73%

Last updated:

EBIT per Employee of Inventage Lab is 2025 -430.02 M KRW. EBIT per Employee of Inventage Lab was 2024 -269.21 M KRW. It decreases by 59.73% lower compared to the previous year.

The Inventage Lab EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2019
-64.79 M KRW
Jan 1, 2020
-83.89 M KRW
Jan 1, 2021
-144.82 M KRW
Jan 1, 2022
-165.18 M KRW
Jan 1, 2023
-408.35 M KRW
Jan 1, 2024
-269.21 M KRW
Jan 1, 2025
-430.02 M KRW
The Inventage Lab EBIT per Employee history
YEAREBIT per EmployeeYoY
-430.02 MKRW+59.73%
-269.21 MKRW-34.07%
-408.35 MKRW+147.22%
-165.18 MKRW+14.06%
-144.82 MKRW+72.62%
-83.89 MKRW+29.48%
-64.79 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventage Lab Stock analysis

What does Inventage Lab do? Inventage Lab, Inc. generates revenue through the research, manufacture, and sale of human medicines targeting male pattern baldness, dementia, and prostate cancer, as well as veterinary medicines including combination drugs and chemical castration agents. The company leverages its proprietary platforms for long-acting injections and genetic material drug delivery to develop and scale production of these products. Its human medicine segment focuses on therapeutic areas with significant market demand, while veterinary medicines serve agricultural and companion animal markets. The firm's business model centers on proprietary technology platforms applied to both human and veterinary pharmaceutical development. These platforms enable the company to create and mass-produce innovative drug delivery systems, which are critical for the efficacy of their medicine portfolios. Revenue streams are derived from direct sales of these medicines to healthcare providers and veterinary institutions within their target markets. Inventage Lab, Inc. operates with a dual focus on human and veterinary pharmaceuticals, utilizing its specialized platforms to address unmet medical needs in both sectors. The company's product range includes treatments for specific conditions like male pattern baldness and prostate cancer, alongside veterinary applications such as chemical castration agents, which are sold to relevant industry stakeholders in their respective markets. Inventage Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventage Lab stock

EBIT per Employee of Inventage Lab is -430.02 M KRW in 2025.

EBIT per Employee of Inventage Lab changed from -269.21 M KRW to -430.02 M KRW, representing a 59.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Inventage Lab since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Inventage Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Inventage Lab

All Key Metrics — Inventage Lab